Praxis gearing up to launch trial of relutrigine in Dravet, other DEEs
Praxis Precision Medicines is gearing up to launch a clinical trial of its experimental anti-seizure therapy relutrigine in people with Dravet syndrome and other disorders that cause seizures in childhood, collectively known as developmental and epileptic encephalopathies (DEEs). According to a corporate presentation, the study, dubbed EMERALD,…